文献速递泌尿男性生殖肿瘤

使用他汀类药物的男性前列腺癌筛查结局

Outcomes of Screening for Prostate Cancer Among Men Who Use Statins.
PubMed 文献 · JAMA Oncol · 2022-01-01

该研究为芬兰前列腺癌筛查随机试验的事后亚组分析,纳入78606名55至67岁男性,按他汀使用分层。他汀非使用者中PSA筛查与前列腺癌发病率增加相关,他汀使用者中未见类似增加,且低级别局限肿瘤检出增加较少,转移瘤检出降低相似。

要点

  • 他汀非使用者中,筛查组较对照组前列腺癌发病率升高(RR 1.31,95%CI 1.24-1.38)。
  • 他汀使用者中,筛查组与对照组前列腺癌发病率无显著差异(RR 1.02,95%CI 0.95-1.10)。
  • 筛查降低转移瘤发生率,此关联与他汀使用无关。

核心结论

  • 他汀使用者中PSA筛查与晚期前列腺癌发病率降低相关且与非使用者相似,但低级别局限肿瘤检出增加较少。
  • 作者认为他汀使用并未实质性损害PSA筛查的获益。

研究设计与样本

  • 基于人群的随机临床试验(芬兰前列腺癌筛查随机研究)的事后亚组队列分析。
  • 1996年3月1日至1999年12月31日随机分组,随访至2015年12月31日。
  • 纳入基线55至67岁、居住于芬兰坦佩雷或赫尔辛基地区的男性,排除基线现患前列腺癌者。
  • 干预为1996至2007年间每4年一次共三次PSA筛查邀请,对照为常规医疗。
  • 共纳入78606名有他汀购买数据的男性,中位年龄59岁(范围55-67岁)。

主要发现

  • 他汀非使用者中,筛查组较对照组前列腺癌发病率升高(11.2 vs 8.6/1000人年;RR 1.31;95%CI 1.24-1.38)。
  • 他汀使用者中,筛查组与对照组前列腺癌发病率无显著差异(6.9 vs 5.9/1000人年;RR 1.02;95%CI 0.95-1.10;交互作用P < .001)。
  • 他汀使用者中低风险(Gleason评分6)和局限肿瘤发病率较低,而Gleason评分8至10肿瘤检出相似。
  • 无论是否使用他汀,筛查均与转移瘤发病率降低相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prostate-specific antigen (PSA) screening for prostate cancer has resulted in a slight reduction in prostate cancer mortality but also a concomitant overdiagnosis of low-risk tumors. Prostate-specific antigen levels are affected by use of cholesterol-lowering statin drugs, but the association of statin use with PSA screening performance is unknown. OBJECTIVE: To investigate whether statin use was associated with outcomes of a randomized PSA-based prostate cancer screening intervention. DESIGN, SETTING, AND PARTICIPANTS: This post hoc subgroup analysis of a cohort from a population-based randomized clinical trial used data from the population-based Finnish Randomized Study of Prostate Cancer Screening, which randomized men to PSA screening or routine care from March 1, 1996, to December 31, 1999, with follow-up continuing until December 31, 2015. The population included all men aged 55 to 67 years at baseline and residing in the Tampere or Helsinki districts of Finland. Information on statin purchases from 1996 to 2009 was obtained from a national prescription registry. Eligible men were identified from the population registry of Finland. Prevalent prostate cancer cases at baseline were excluded. Data were analyzed from January 1, 2019 to March 31, 2021. INTERVENTIONS: Three invitations for PSA screening at 4-year intervals from 1996 to 2007 vs routine care. MAIN OUTCOMES AND MEASURES: Risk for prostate cancer overall, high-risk disease, and prostate cancer mortality in the screening group vs the control group as an intention-to-treat analysis. The analysis was stratified by statin use. RESULTS: The study comprised 78 606 men (median age, 59 years [range, 55-67 years]) with statin purchase data available. Although PSA screening was associated with increased prostate cancer incidence among statin nonusers (screening vs control, 11.2 vs 8.6 per 1000 person-years); rate ratio [RR], 1.31; 95% CI, 1.24-1.38), no similar increase in incidence was observed among statin users (6.9 vs 5.9 per 1000 person-years; RR, 1.02; 95% CI, 0.95-1.10; P < .001 for interaction). Incidence of low-risk (Gleason score 6) and localized tumors was lower among statin users, whereas detection of tumors with a Gleason score of 8 to 10 was similar. Screening was associated with a lower incidence of metastatic tumors regardless of statin use. CONCLUSION AND RELEVANCE: In this post hoc subgroup analysis of a cohort from a population-based randomized clinical trial, PSA screening among statin users was associated with a decreased incidence of advanced prostate cancer that was similar among statin nonusers, but with less increase in detection of low-grade localized tumors in statin users than in nonusers. These findings suggest that statin use does not materially compromise benefits of PSA-based screening.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Vettenranta A, Murtola TJ, Raitanen J, et al. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. JAMA Oncol. 2022. PMID: 34817559. doi:10.1001/jamaoncol.2021.5672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。